Short answer
Travere Therapeutics, Inc. (TVTX) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $127M (up 55.6% year over year) with net income of −$37M.
Q1 2026 key financials · XBRL
- Revenue
- $127M
- +55.6% YoY
- Net income
- −$37M
- +10.0% YoY
- Operating margin
- -29.0%
- EPS (diluted)
- −$0.40
- +14.9% YoY
Source: XBRL data from the Travere Therapeutics, Inc. (TVTX) Q1 2026 10-Q on SEC EDGAR. USD.
Travere Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $127.2M, up $45.5M YoY from $81.7M
- FILSPARI sales $105.2M, up $49.3M YoY; best-performing product line
- Tiopronin sales $19.3M, down $0.6M YoY; weakest product performance
- R&D expense $57.1M, up $10.2M, driven by HARMONY enrollment restart
- FSGS launch investments and HARMONY manufacturing restart cited as near-term spending drivers
Risk Factors
- Newly added FSGS commercialization risk triggered by FDA traditional approval in April 2026 and expanded FILSPARI launch requirements
- Most materially updated partner risk following Renalys’s fourth-quarter 2025 acquisition by Chugai, potentially reducing sparsentan commercialization resources
- Regulatory pricing risk from May 2025 most-favored-nation executive order targeting international reference pricing for prescription drugs
- Competitive risk from generic Thiola and Thiola EC entrants, including multiple FDA-approved options for 100mg and 300mg formulations
- Supply-chain risk from sole-source third-party manufacturers and tariffs affecting materials sourced from certain countries
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Travere Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.